Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

LATE-BREAKING ABSTRACT: Reslizumab in patients with late-onset asthma with elevated blood eosinophils

Guy Brusselle, Matthew Germinaro, Sherrine Eid, James Zangrilli
European Respiratory Journal 2015 46: OA287; DOI: 10.1183/13993003.congress-2015.OA287
Guy Brusselle
1Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Germinaro
2Global Respiratory Research and Development, Teva Pharmaceuticals, Frazer, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sherrine Eid
3Biostatistics, Teva Pharmaceuticals, Frazer, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Zangrilli
4Global Respiratory Research and Development, Global Branded Products, Teva Pharmaceuticals, Frazer, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Figures

  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint
Previous
Back to top
Vol 46 Issue suppl 59 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
LATE-BREAKING ABSTRACT: Reslizumab in patients with late-onset asthma with elevated blood eosinophils
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
LATE-BREAKING ABSTRACT: Reslizumab in patients with late-onset asthma with elevated blood eosinophils
Guy Brusselle, Matthew Germinaro, Sherrine Eid, James Zangrilli
European Respiratory Journal Sep 2015, 46 (suppl 59) OA287; DOI: 10.1183/13993003.congress-2015.OA287

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
LATE-BREAKING ABSTRACT: Reslizumab in patients with late-onset asthma with elevated blood eosinophils
Guy Brusselle, Matthew Germinaro, Sherrine Eid, James Zangrilli
European Respiratory Journal Sep 2015, 46 (suppl 59) OA287; DOI: 10.1183/13993003.congress-2015.OA287
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Pharmacological characterization of the anti-oxidant activity of N-acetylcysteine in an ex vivo model of COPD exacerbation
  • TNFAIP3 (A20) expression is elevated in the sputum of severe asthmatics
  • Neurokinin-1 receptor antagonism for the treatment of cough in lung cancer
Show more 5.1 Airway Pharmacology and Treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society